Verici Dx (LSE:VRCI) Capex-to-Operating-Income : 0.00 (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Verici Dx Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Verici Dx's Capital Expenditure for the six months ended in Jun. 2024 was £-0.08 Mil. Its Operating Income for the six months ended in Jun. 2024 was £-1.14 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Verici Dx Capex-to-Operating-Income Historical Data

The historical data trend for Verici Dx's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Capex-to-Operating-Income Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Income

Verici Dx Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Capex-to-Operating-Income	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Verici Dx's Capex-to-Operating-Income

For the Diagnostics & Research subindustry, Verici Dx's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verici Dx's Capex-to-Operating-Income Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Verici Dx's Capex-to-Operating-Income falls into.

Save Embed

;

Save Embed

;

Verici Dx Capex-to-Operating-Income Calculation

Verici Dx's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.182)	/	-7.005
	=	N/A

Verici Dx's Capex-to-Operating-Income for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.075)	/	-1.142
	=	N/A

Verici Dx (LSE:VRCI) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Verici Dx Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Verici Dx's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (LSE:VRCI) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

63V:Germany

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines